Volume 15, Number 2—February 2009
Research
Methicillin-Susceptible Staphylococcus aureus in Skin and Soft Tissue Infections, Northern Italy
Table 1
Characteristics of patients with community-acquired MSSA skin and soft tissue infections, their treatment, and molecular typing of the isolates, northern Italy, 2004–2006*
Patient | Age, sex | Site of infection† | Type of infection† | Antimicrobial drug treatment† | Drainage | Molecular typing of MSSA isolates |
|||
---|---|---|---|---|---|---|---|---|---|
Presence of PVL genes | PFGE type | spa type | ST | ||||||
Family clusters | |||||||||
Cluster 1 | |||||||||
P 1 | 32 y, F | Leg | Abscess | None | Spontaneous | NA | |||
P 2 | 33 y, M | Axilla | Abscesses | AMC, CIP | None | NA | |||
P 3 | 4 d, M | Prepuce | Pustules | GEN | None | NA | |||
Cluster 2 | |||||||||
P 4 | 30 y, F | Vulva, thighs | Pustules, abscesses | AMC, LFX, TEC | None | + | A | t005 | 22 |
P 5 | 33 y, M | Nose, scalp | Pustules | AMC | None | NA | |||
P 6 | 14 mo, F | Thigh | Pustules | CLI | None | NA | |||
P 7 | 14 d, F | Thigh | Pustules | CLI | None | + | A | t005 | ND |
Cluster 3 | |||||||||
P 8 | 32 y, F | Face, vulva, leg | Abscesses | AMC, CIP, LFX | None | + | A | t005 | 22 |
P 9 | 25 mo, F | Leg | Abscess | None | Spontaneous | NA | |||
Cluster 4 | |||||||||
P 10 | 34 y, F | Axilla, forearm, leg | Abscesses | AMC | None | NA | |||
P 11 | 35 y, M | Axilla, forearm, leg | Abscess, furuncles | AMC, LFX | Surgical | + | A | t005 | ND |
P 12 | 4 d, M | Neck, groin, axilla, | Pustules, abscesses | AMC, AMC | Spontaneous | + | A | t005 | 22 |
P 13 | 3 y, M | Forearm | Abscesses | AMC | None | NA | |||
P 14 | 65 y, F | Axilla, forearm, leg, face | Abscess | None | None | NA | |||
Cluster 5 | |||||||||
P 15 | 33 y, F | Face, leg, axilla | Pustules, abscess | AMC | Surgical | NA | |||
P 16 |
36 y, M |
Thigh |
Furuncles, abscess |
AMC |
None |
NA |
|||
Sporadic cases | |||||||||
P 17 | 64 y, F | Axilla | Abscess | CIP | None | + | A | t005 | 22 |
P 18 | 7 mo, F | Arm | Pustules | AMC | None | – | F | t159 | ND |
P 19 | 9 y, F | Axilla | Furuncles | AMC | None | – | F | t159 | ND |
P 20 | 12 mo, M | Groin | Abscess | AMC | None | + | A | t005 | ND |
P 21 | 8 y, F | Leg | Abscess | AMC | None | – | G | t445 | ND |
P 22 | 18 mo, M | Forearm | Furuncles | AMC | None | + | A | t005 | ND |
P 23 | 12 mo, F | Buttock | Abscess | AMC | Spontaneous | + | A | t005 | ND |
P 24 | 20 mo, F | Thigh | Abscess | AMC | None | + | A | t005 | 22 |
P 25 | 8 y, M | Arm, chest | Abscesses | AMC | Surgical | + | A | t005 | ND |
P 26 | 11 y, M | Face, eye | Abscess, conjunctivitis | AMC | None | + | A | t005 | 22 |
*MSSA, methicillin-susceptible Staphylococcus aureus; PVL, Panton-Valentine leukocidin; PFGE, pulsed-field gel electrophoresis; ST, sequence type; NA, isolate not available; AMC, amoxicillin-clavulanic acid; CIP, ciprofloxacin; GEN, gentamicin (topical); LFX, levofloxacin; TEC, teicoplanin; CLI, clindamycin (topical); ND, not determined.
†When >1 site or type of infection or antibimicrobial agents are indicated, they refer to different infection episodes.